And paediatric clients with liver disease and in obstetric and gynaecological emergenciesV Chekrizova, W Murphy Irish Blood Transfusion Company, Dublin, Ireland Critical Care 2006, ten(Suppl 1):P163 (doi:ten.1186/cc4510) We assessed the efficacy and tolerance of solvent-detergent (SD) plasma in neonates, in obstetric and gynaecological sufferers, as well as in people with liver sickness in three substantial hospitals in Dublin more than an 18-month interval. Forty-one neonates obtained sixty seven transfusions of SD plasma in a indicate dose ?regular deviation of 18.four ?three.two ml/kg. Thirty-eight obstetric and gynaecological sufferers been given 57 SD plasma transfusions in a suggest dose of fifteen.three ?seven.7 ml/kg. Thirty-six ladies (94.seven ) experienced haemorrhage with mean blood loss for each affected person of 3345.eight ?2738.1 ml. Fifteen kids with liver illness obtained 33 SD plasma transfusions in a mean quantity of 38.0 ?41.5 ml/kg body excess weight. Seventeen adult people with severe end-stage liver ailment ended up transfused with SD plasma possibly subsequent liver transplantation or ahead of other invasive processes, at a necessarily mean dose of ten.two ?3.four ml/kg. There have been statistically significant decreases in APTT and PT in neonates, in obstetric and gynaecological sufferers, and in individuals with liver condition. Pre-transfusion and post-transfusion APTT was measured in 40/67 neonatal transfusion PR-39 episodes, PT in 43/67, fibrinogen in 39/67, and platelets in 49/67. Following plasma infusion the indicate APTT enhanced PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/2805811 from sixty eight.nine ?37.four s to forty four.0 ?15.six s (t = 4.seventy nine; P < 0.001); PT from 28.7 ?20.3 s to 20.7 ?14.2 s (t = 2.64; P < 0.02); fibrinogen from 1.94 ?1.1 g/l to 2.51 ?1.14 g/l (t = 3.41; P < 0.002). Pre-transfusion and post-transfusion APTT was measured in 41/57 transfusions in the obstetric/gynaecology group; PT and fibrinogen in 42/57. The mean APTT improved from 50.1 ?18.4 s to 32.7 ?6.9 s (t = 6.40; P < 0.001); PT from 21.0 ?5.2 s to 15.6 ?1.9 s (t = 7.71; P < 0.001); fibrinogen from 1.55 ?0.75 g/l to 2.74 ?0.86 g/l (t = 9.15; P < 0.001). Pretransfusion and post-transfusion APTT, PT and platelets were measured in 22/33 transfusion episodes in the group of children with liver disease, and fibrinogen in 13/33. The APTT decreased from 61.5 ?33.0 s to 47.8 ?12.5 s (t = 5.15, P < 0.001) and the PT from 24.4 ?10.0 s to 19.9 ?4.2 s (t = 5.05, P < 0.001). Fibrinogen improved from 1.46 ?0.75 g/l to 1.66 ?0.59 g/l (t = 1.25; P > 0.05). In the team of grownup people with critical endstage liver disorder, precoagulation and postcoagulation check benefits ended up obtainable for 14 of 17 transfusion episodes. There was a statistically sizeable improvement in the PT from 23.2 ?4.nine sP162 Ongoing administration of LMWH in critical sufferers: a contribution to the monitoring of hemocoagulationZ Stach1, J Valenta1, P Salaj2, I Hrachovinova2, I Marinov2, M Stritesky1 1General Teaching Hospital, 1st Professional medical College of Charles College Prague, Czech Republic; 2Institut of Hematology and Blood Transfusion, Prague, Czech Republic Important Treatment 2006, 10(Suppl 1):P162 (doi:ten.1186/cc4509) Goal To watch hemocoagulation in sufferers with systemic irritation although regularly i.v. administering LMWH, in addition dosage PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/7891282 adjustment, whilst trying to mirror on coagulation modifications, predominantly concerning the values of anti-Xa and Ddim. History LMWH is used in the prophylaxis of in addition as treatment of DVT, while in the prevention of thrombus formation in extracorporal circulation as a result of CRRT, inside the treatment of unstable angina pectoris and non-Q myocardial infarction,.